Efficacy of PD-1-inhibitor-based Combination Therapy in Patients With Metastatic Colorectal Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 97
- 试验地点
- 1
- 主要终点
- Durable clinical benefit
研究概览
简要总结
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment
- •patients with identified genomic status
排除标准
- •patients who received immune monotherapy
- •patients who stopped treatment for any reason without identified response assessment.
研究组 & 干预措施
Combination treatment
PD-1 inhibitor-based combination treatment
干预措施: Combinations (Drug)
结局指标
主要结局
Durable clinical benefit
时间窗: immediately after the intervention
Rate of patients who acheived CR or PR or SD that lasted more than 6 months
次要结局
未报告次要终点
研究者
Feng Ye
Chief physician
First Affiliated Hospital of Zhejiang University